14th International Congress of Parkinson's Disease and Movement Disorders
Teaching Course Session 2309: Update on dystonia
This course will cover the spectrum of dystonias, providing insight into diagnosis and treatment. The course will begin with the classification into primary and secondary dystonias, followed by further examination into genetic, heredodegenerative and paroxysmal dystonias. This program has a special emphasis on the various phenotypes of genetic forms of dystonia, including the recently discovered forms associated with DYT6. Secondary dystonia is described with detailed clinical syndromic associations.
At the conclusion of this course, participants should be able to:
- Describe the phenotypes of primary and secondary dystonia
- Identify the major indications for genetic testing in dystonia
- Develop a strategy to manage and treat dystonic syndromes
This course is recommended for general neurologists, geriatricians, and internists.
Relationship Disclosure Policy
It is the policy of The Movement Disorder Society (MDS) to ensure balance, independence, objectivity, and scientific rigor in all MDS-sponsored educational activities. All planning committee and faculty members participating in any MDS-sponsored activity are required to disclose to MDS and the activity audience all relevant financial relationships with any commercial interest. This disclosure will be provided to all participants prior to the beginning of the Continuing Medical Education (CME) activity. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified and resolved prior to the activity, so that there is no commercial bias present in the presentation.
Faculty Relationship Disclosures
- Kailash Bhatia has received grants from Allergan, Kyowa, and GlaxoSmithKline; and has received honoraria from Ipsen, Allergan, Kyowa, GlaxoSmithKline, and Merz
- Silvia Garcia has indicated that there are no industry relationships to disclose
- Rachel Saunders-Pullman has received grants from National Institutes of Health, Bachmann-Strauss Dystonia and Parkinson's Foundation, and Michael J. Fox Foundation for Parkinson's Research
- Kapil Sethi has worked as a consultant for GlaxoSmithKline, Boehringer Ingelheim, Novartis, Solvay, Ipsen, UCB, and Teva; has received grants from GlaxoSmithKline, Novartis, and Solvay, Allergan; and has received honoraria from GlaxoSmithKline, BI, Novartis, Solvay, UCB, and Teva